<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="other"><?properties open_access?><!-- Original-type: cl--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">15188010</article-id><article-id pub-id-type="pmc">2364756</article-id><article-id pub-id-type="pii">6601891</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6601891</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical</subject></subj-group></article-categories><title-group><article-title>Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lee</surname><given-names>S-H</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kang</surname><given-names>W K</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>H Y</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>J H</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>S I</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>J O</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>K</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Jung</surname><given-names>C W</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Y S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Im</surname><given-names>Y-H</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>M H</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>K</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label><sup>1</sup>Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon-dong, Kangnam-gu, Seoul 135-710, Korea</aff><author-notes><corresp id="caf1"><label>*</label>Author for correspondence: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:wkkang@smc.samsung.co.kr">wkkang@smc.samsung.co.kr</email></corresp></author-notes><pub-date pub-type="epub"><day>08</day><month>06</month><year>2004</year></pub-date><pub-date pub-type="collection"><day>29</day><month>06</month><year>2004</year></pub-date><pub-date pub-type="ppub"><day>05</day><month>07</month><year>2004</year></pub-date><volume>91</volume><issue>1</issue><fpage>18</fpage><lpage>22</lpage><history><date date-type="received"><day>04</day><month>02</month><year>2004</year></date><date date-type="rev-recd"><day>14</day><month>04</month><year>2004</year></date><date date-type="accepted"><day>19</day><month>04</month><year>2004</year></date></history><copyright-statement>Copyright 2004, Cancer Research UK</copyright-statement><copyright-year>2004</copyright-year><permissions><copyright-holder>Cancer Research UK</copyright-holder></permissions><kwd-group><kwd>chemotherapy</kwd><kwd>cisplatin</kwd><kwd>docetaxel</kwd><kwd>epirubicin</kwd><kwd>gastric carcinoma</kwd></kwd-group></article-meta></front><body><p>Gastric cancer is the most common malignancy in Korea (<xref ref-type="other" rid="bib4">Bae <italic>et al</italic>, 2002</xref>). The prognosis of unresectable gastric cancer has been improved by cytotoxic chemotherapy, but median survival rarely exceeds 1 year (<xref ref-type="other" rid="bib16">Pyrhonen <italic>et al</italic>, 1995</xref>; <xref ref-type="other" rid="bib9">Glimelius <italic>et al</italic>, 1997</xref>; <xref ref-type="other" rid="bib22">Webb <italic>et al</italic>, 1997</xref>; <xref ref-type="other" rid="bib13">Ohtsu <italic>et al</italic>, 2003</xref>).</p><p>Single agents such as doxorubicin, cisplatin, 5-fluorouracil (5-FU) and mitomycin-C have modest activities, showing response rates of about 20&#x00025; against gastric cancer. The median duration of response is usually between 3 and 4 months, and occasional complete responses (CRs) have been noted (<xref ref-type="other" rid="bib12">Moertel and Lavin, 1979</xref>; <xref ref-type="other" rid="bib6">Cocconi <italic>et al</italic>, 1982</xref>; <xref ref-type="other" rid="bib1">Aabo <italic>et al</italic>, 1985</xref>).</p><p>Many combinations of cytotoxic chemotherapeutic agents have been developed to improve the remission rate and duration of survival. In the late 1980s and early 1990s, FAM (5-FU, doxorubicin, mitomycin-C), FP (5-FU, cisplatin), FAMTX (5-FU, doxorubicin, methotrexate), EAP (etoposide, doxorubicin, cisplatin) and ECF (epirubicin, cisplatin, protracted 5-FU) showed high response rates in phase II trials, but lower response rates and overall survival (OS) of less than 1 year in randomised trials (<xref ref-type="other" rid="bib23">Wilke and Cutsem, 2003</xref>). Randomised trials showed FAMTX was superior to FAM (in efficacy) and EAP (in safety), and ECF was superior to FAMTX in terms of response rate and survival (<xref ref-type="other" rid="bib24">Wils <italic>et al</italic>, 1991</xref>; <xref ref-type="other" rid="bib10">Kelsen <italic>et al</italic>, 1992</xref>; <xref ref-type="other" rid="bib22">Webb <italic>et al</italic>, 1997</xref>). However, the median survival of the ECF regimen ranged from 8 to 10 months in the phase III trials (<xref ref-type="other" rid="bib22">Webb <italic>et al</italic>, 1997</xref>; <xref ref-type="other" rid="bib18">Ross <italic>et al</italic>, 2002</xref>).</p><p>New agents such as taxane, irinotecan and oxaliplatin combined with old agents such as cisplatin and 5-fluorouracil are currently under evaluation to further improve treatment outcome (<xref ref-type="other" rid="bib23">Wilke and Cutsem, 2003</xref>). Docetaxel as a single agent showed response rates of 17&#x02013;24&#x00025; (<xref ref-type="other" rid="bib20">Sulkes <italic>et al</italic>, 1994</xref>; <xref ref-type="other" rid="bib7">Einzig <italic>et al</italic>, 1996</xref>), and the combination of docetaxel and cisplatin has shown a response rate of 37&#x02013;56&#x00025; and OS of 9&#x02013;10.4 months (<xref ref-type="other" rid="bib19">Roth <italic>et al</italic>, 2000</xref>; <xref ref-type="other" rid="bib17">Ridwelski <italic>et al</italic>, 2001</xref>).</p><p>Although the combination of docetaxel and anthracycline has not been studied enough in gastric cancer, the synergism between docetaxel and anthracycline is well established in other cancers, especially breast cancer (<xref ref-type="other" rid="bib14">Pagani <italic>et al</italic>, 2000</xref>). Compared with doxorubicin, epirubicin has the advantages of less cardiotoxicity and less myelosuppression, with similar cytotoxic effect (<xref ref-type="other" rid="bib5">Cersosimo and Hong, 1986</xref>; <xref ref-type="other" rid="bib21">Vorobiof and Falkson, 1989</xref>). A combination of epirubicin and docetaxel showed a response rate of 22&#x00025; and progression-free survival of 16 weeks when used as a second-line treatment in advanced gastric cancer (<xref ref-type="other" rid="bib3">Andre <italic>et al</italic>, 1999</xref>). In addition, epirubicin has proven to have synergistic clinical effect with cisplatin (<xref ref-type="other" rid="bib11">Kyoto Research Group for Chemotherapy of Gastric Cancer, 1992</xref>) in gastric cancer.</p><p>Combination chemotherapy with 40&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> of epirubicin, 75&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> of docetaxel and 75&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> of cisplatin were administered in transitional cell carcinoma (<xref ref-type="other" rid="bib15">Pectasides <italic>et al</italic>, 2000</xref>). The study reported tolerable toxicity profiles, but 53&#x00025; of the patients were required at least one dose reduction due to haematological toxicities. According to the findings of the study, we planned to administer 60&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> of docetaxel instead of 75&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> in combination with the other two drugs.</p><p>Based on the single agent activities of epirubicin, docetaxel and cisplatin (EDP), and the additive or synergistic clinical effects of these three drugs in gastric cancer, we performed a phase II trial of combination chemotherapy with EDP for patients with metastatic or recurrent, unresectable gastric cancer.</p><sec sec-type="materials|methods"><title>MATERIALS AND METHODS</title><p>This was an open-label, single institution, phase II study of combination therapy with EDP in metastatic or recurrent, unresectable gastric cancer. Patients were enrolled at Samsung Medical Center between January 2002 and February 2003. The study was approved by the institutional review board, and written informed consent was obtained from each patient.</p><sec><title>Patient eligibility</title><p>Patients with histologically confirmed metastatic or recurrent, unresectable gastric adenocarcinoma were eligible for this study. Actually all patients had metastatic gastric adenocarcinoma, with or without history of surgery with curative intent. All patients were required to be between 18 and 70 years, to have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0&#x02013;2, and to have bidimensionally measurable disease (defined as the presence of at least one index lesion capable of two-dimensional measurement by computed tomography scan or chest X-ray above 2&#x02009;cm in greatest diameter). Any history of chemotherapy for palliation was not allowed, but adjuvant chemotherapy elapsing more than 12 months previously was allowed. Other eligibility criteria included an absolute neutrophil count (ANC) &#x02a7e;1500&#x02009;mm<sup>&#x02212;3</sup>, a platelet count &#x02a7e;100&#x02009;000&#x02009;mm<sup>&#x02212;3</sup>, serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) activities &#x02a7d;3.0 times the upper normal limit (UNL) (in cases of liver metastasis, AST and ALT &#x02a7d;5.0 UNL), serum bilirubin level &#x02a7d;1.25 times UNL, creatinine clearance (Cockroft formula) &#x02a7e;60&#x02009;ml&#x02009;min<sup>&#x02212;1</sup> and left ventricular ejection fraction &#x02a7e;50&#x00025;. Patients with metastasis to the central nervous system were excluded from the study. Prior history of another malignancy within 5 years of study entry, apart from basal cell carcinoma of the skin or carcinoma <italic>in situ</italic> of the uterine cervix, or grade 2&#x02013;4 peripheral neuropathy, precluded participation in the current trial. Patients with clinically significant cardiac disease as defined by symptomatic ventricular arrhythmias, history of congestive heart failure, or history of previous myocardial infarction within 12 months of study entry were also excluded.</p></sec></sec><sec><title>STUDY PROTOCOL</title><p>Patients received 40&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> (reduced to 30&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> due to unexpectedly high incidence of febrile neutropaenia; 75&#x00025;) of epirubicin intravenously (i.v.) over 30&#x02009;min, followed by 60&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> of docetaxel i.v. over 1&#x02009;h, and then followed by 75&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> of cisplatin i.v. over 1&#x02009;h on day 1. Cycles were repeated every 3 weeks. Dexamethasone premedication was used for prophylaxis of docetaxel-induced hypersensitivity and fluid retention. Adequate hydration and intravenous mannitol were used for the prophylaxis of cisplatin-induced nephrotoxicity. Half saline 1000&#x02009;ml plus KCl 20&#x02009;mEq was administered intravenously over 2&#x02009;h each before and after cisplatin. Patients were discontinued from the study therapy when there was evidence of disease progression, the patient experienced unacceptable toxicity, the patient requested discontinuation, or the investigator decided that the patient should be withdrawn.</p><p>The primary end point of the trial was response rate. The secondary end points were duration of response, time to progression (TTP), OS and toxicity.</p><sec><title>Dose modification</title><p>Chemotherapy was withheld if the ANC was &#x0003c;1500&#x02009;mm<sup>&#x02212;3</sup> or the platelet count was &#x0003c;100&#x02009;000&#x02009;mm<sup>&#x02212;3</sup> on day 1. In this case, the complete blood cell count was repeated at least weekly and chemotherapy was restarted as soon as the ANC reached &#x02a7e;1500&#x02009;mm<sup>&#x02212;3</sup> and platelet count &#x02a7e;100&#x02009;000&#x02009;mm<sup>&#x02212;3</sup>. If nadir ANC was less than 500&#x02009;mm<sup>&#x02212;3</sup> or the nadir platelet count was less than 50&#x02009;000&#x02009;mm<sup>&#x02212;3</sup>, the doses of epirubicin and docetaxel were reduced to 30 and 45&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>, respectively, and in the patients who received 30&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> of epirubicin, docetaxel alone was reduced to 45&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>. If the calculated creatinine clearance (Ccr) was less than 50&#x02009;ml&#x02009;min<sup>&#x02212;1</sup>, treatment was delayed, and serum creatinine was measured weekly. Treatment was resumed if calculated Ccr increased above 50&#x02009;ml&#x02009;min<sup>&#x02212;1</sup>; if this increase was not achieved by day 35, the patient was taken off study. If the calculated Ccr was 50&#x02013;59&#x02009;ml&#x02009;min<sup>&#x02212;1</sup> at any time, cisplatin was administered with the dose of 60&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>. If grade 3&#x02013;4 neurotoxicity or ototoxicity occurred, cisplatin was withheld in the subsequent cycles. If grade 3&#x02013;4 nausea or vomiting was not controlled with adequate management, cisplatin was reduced to 60&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>. If grade 3&#x02013;4 nonhaematologic toxicity other than alopecia and those above mentioned, the treatment was withheld until recovery to grade 0 or 1 and the doses of epirubicin and docetaxel were reduced to 30 and 45&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>, respectively, and in the patients who received 30&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> of epirubicin, docetaxel alone was reduced to 45&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>. If patients required a delay of longer than 2 weeks, they were removed from the study.</p></sec><sec><title>Assessment of efficacy and toxicity</title><p>At study entry, the following investigations were performed: full history taking and physical examination, complete blood cell count (CBC), chemistry, chest X-ray, echocardiography and computed tomography scan. All investigations except echocardiography were repeated before every cycle. Computed tomography scans were performed optimally to document disease extent and to evaluate response to treatment, every two cycles and when needed for the confirmation of response and suspected disease progression. CBC was repeated every week during the first cycle and the following cycle if the patient experienced grade 4 haematologic toxicity. Otherwise, CBC was repeated every 3 weeks.</p><p>Complete response was defined as the complete disappearance of all clinically detectable disease for at least 4 weeks. Partial response (PR) was defined as a more than 50&#x00025; decrease in the sum of the products of the two longest perpendicular diameters of all measurable lesions for at least 4 weeks with no increase in size of any area of known malignant disease and no appearance of new areas of malignant disease. Progressive disease (PD) was defined as a greater than 25&#x00025; increase in the sum of the products of the perpendicular diameters of all measurable lesions or the appearance of any new lesion. All other outcomes were scored as stable disease (SD).</p><p>Response rate was calculated as the ratio of number of patients who achieved CR or PR to the number of intent-to-treat (ITT) patients.</p><p>Duration of response was calculated from the first day of treatment to the date on which PD was first observed or of the last follow-up, for the group of responding patients. Time to progression was calculated from the first day of treatment to the date on which PD was first observed or of the last follow-up. Overall survival was calculated from the first day of treatment to the date of death or last follow-up.</p><p>Toxicity was assessed according to the National Cancer Institute common toxicity criteria (NCI-CTC) scale version 2.0. The severity of any toxicities not defined in the NCI-CTC were graded as 1&#x0003d;mild, 2&#x0003d;moderate, 3&#x0003d;severe or 4&#x0003d;very severe.</p></sec><sec><title>Statistical analysis</title><p>Descriptive statistics were reported as proportions and medians. Kaplan&#x02013;Meier estimates were used in the analysis of all time-to-event variables, and the 95&#x00025; confidence interval (CI) for the median time to event was computed. The dose intensity (DI) was calculated as the ratio of the total dose (expressed in milligrams) per square metre of the patient, divided by the total treatment duration expressed in days. In this calculation, the end of treatment was considered to be 21 days after day 1 of the last cycle of chemotherapy. The relative DI was calculated as the ratio of the DI actually delivered to the DI planned by the protocol.</p><p>According to Simon's two-stage optimal design, a sample size of 25 was required to accept the hypothesis that the true response rate is greater than 45 with 80&#x00025; power, and to reject the hypothesis that the response rate is less than 20 with 5&#x00025; significance. At the first stage, if there were fewer than two responses out of the initial 15 patients, the study would terminate. Although the target number of patients was 25, we planned to recruit 20&#x00025; more than the target number of patients considering drop-out.</p><p>SPSS for Windows (SPSS Inc., Chicago, IL, USA) was used for statistical analysis.</p></sec></sec><sec><title>RESULTS</title><sec><title>Patient characteristics</title><p>From January 2002 to February 2003, 30 patients were enrolled. The clinical characteristics of the enrolled patients are provided in <xref rid="tbl1" ref-type="table">Table 1</xref>
 <table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p content-type="table-title">Patient characteristics</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Characteristic</bold></th><th align="center" valign="top" charoff="50"><bold>Number of patients</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Eligible&#x0002f;total patients</td><td align="center" valign="top" charoff="50">30&#x0002f;30</td></tr><tr><td align="left" valign="top" charoff="50">Age (years: median (range))</td><td align="center" valign="top" charoff="50">52 (33&#x02013;68)</td></tr><tr><td align="left" valign="top" charoff="50">Male&#x0002f;female</td><td align="center" valign="top" charoff="50">25&#x0002f;5</td></tr><tr><td align="left" valign="top" charoff="50">Performance status: ECOG 0&#x0002f;1</td><td align="center" valign="top" charoff="50">3&#x0002f;27</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="2" align="left" valign="top" charoff="50"><italic>Grade</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Moderately differentiated</td><td align="char" valign="top" char="." charoff="50">7</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Poorly differentiated</td><td align="char" valign="top" char="." charoff="50">21</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="2" align="left" valign="top" charoff="50"><italic>Predominant metastatic sites</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Liver</td><td align="char" valign="top" char="." charoff="50">11</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Lymph node</td><td align="char" valign="top" char="." charoff="50">15</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Peritoneum</td><td align="char" valign="top" char="." charoff="50">1</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Others</td><td align="char" valign="top" char="." charoff="50">3</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="2" align="left" valign="top" charoff="50"><italic>Previous treatment</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Surgery with curative intent</td><td align="char" valign="top" char="." charoff="50">4</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Palliative surgery</td><td align="char" valign="top" char="." charoff="50">9</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02003;Gastrectomy</td><td align="char" valign="top" char="." charoff="50">8</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02003;Metastasectomy</td><td align="char" valign="top" char="." charoff="50">2</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Adjuvant chemoradiation</td><td align="char" valign="top" char="." charoff="50">1</td></tr></tbody></table></table-wrap>. All patients had gastric adenocarcinoma. It did not include tumours of gastroesophageal junction. The median age was 52 years (range, 33&#x02013;68), and there were 25 (83&#x00025;) men and five women. Four patients received surgery with curative intent, with a disease-free interval of 9&#x02013;32 months. Another nine patients received palliative debulking surgery 1&#x02013;2 months before the study. The major involved organs were liver and intra-abdominal lymph nodes.</p></sec><sec><title>Delivery of drug</title><p>The patients received a median of four (range, 1&#x02013;8) cycles. The average relative dose-intensity was 0.92 for epirubicin, 0.86 for docetaxel and 0.90 for cisplatin in the patients who received 30&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> epirubicin. Dose reduction was required in eight patients (eight cycles) and treatment was delayed in seven patients (nine cycles) out of 22 patients who received 30&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> epirubicin.</p></sec><sec><title>Efficacy</title><p>All 30 patients were evaluable for response. We observed one CR, 13 PRs and 13 SDs (<xref rid="tbl2" ref-type="table">Table 2</xref>
 <table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p content-type="table-title">Response to combination chemotherapy</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Response</bold></th><th align="char" valign="top" char="." charoff="50"><bold>Total (<italic>N</italic>&#x0003d;30)</bold></th><th align="char" valign="top" char="." charoff="50"><bold>Epi 30&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> (<italic>N</italic>&#x0003d;22)</bold></th><th align="center" valign="top" charoff="50"><bold>Epi 40&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> (<italic>N</italic>&#x0003d;8)</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Complete response</td><td align="char" valign="top" char="." charoff="50">1 (3&#x00025;)</td><td align="char" valign="top" char="." charoff="50">1 (5&#x00025;)</td><td align="center" valign="top" charoff="50">0</td></tr><tr><td align="left" valign="top" charoff="50">Partial response</td><td align="char" valign="top" char="." charoff="50">13 (43&#x00025;)</td><td align="char" valign="top" char="." charoff="50">9 (41&#x00025;)</td><td align="char" valign="top" char="." charoff="50">4 (50&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">Stable disease</td><td align="char" valign="top" char="." charoff="50">13 (43&#x00025;)</td><td align="char" valign="top" char="." charoff="50">9 (41&#x00025;)</td><td align="char" valign="top" char="." charoff="50">4 (50&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">Progressive disease</td><td align="char" valign="top" char="." charoff="50">3 (10&#x00025;)</td><td align="char" valign="top" char="." charoff="50">3 (14&#x00025;)</td><td align="center" valign="top" charoff="50">0</td></tr></tbody></table><table-wrap-foot><fn id="tbfnote1"><label/><p>Epi&#x0003d;epirubicin.</p></fn></table-wrap-foot></table-wrap>). The response rate was 47&#x00025; (95&#x00025; CI, 28&#x02013;66&#x00025;), and the median duration of response was 5.0 months (95&#x00025; CI, 3.0&#x02013;7.0) for all responders. The median follow-up time was 17.7 months. The median TTP was 4.1 months (95&#x00025; CI, 2.4&#x02013;5.9), and the median OS was 11.0 months (95&#x00025; CI, 9.5&#x02013;12.4) (<xref ref-type="fig" rid="fig1">Figure 1</xref><fig id="fig1"><label>Figure 1</label><caption><p>Overall survival (OS) and time to progression (TTP) curve.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="gif" xlink:href="91-6601891f1"/></fig>).</p></sec><sec><title>Toxicity</title><p><xref rid="tbl3" ref-type="table">Table 3</xref>
 <table-wrap id="tbl3" position="float"><label>Table 3</label><caption><p content-type="table-title">Toxicity of combination chemotherapy</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Toxicity</bold></th><th align="char" valign="top" char="." charoff="50"><bold>Grade 1</bold></th><th align="char" valign="top" char="." charoff="50"><bold>Grade 2</bold></th><th align="char" valign="top" char="." charoff="50"><bold>Grade 3</bold></th><th align="char" valign="top" char="." charoff="50"><bold>Grade 4</bold></th></tr></thead><tbody valign="top"><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Haematological toxicity (30 patients; maximal grade)</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Leucopaenia</td><td align="char" valign="top" char="." charoff="50">5 (17&#x00025;)</td><td align="char" valign="top" char="." charoff="50">6 (20&#x00025;)</td><td align="char" valign="top" char="." charoff="50">9 (30&#x00025;)</td><td align="char" valign="top" char="." charoff="50">7 (23&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Neutropaenia</td><td align="char" valign="top" char="." charoff="50">3 (10&#x00025;)</td><td align="char" valign="top" char="." charoff="50">2 (7&#x00025;)</td><td align="char" valign="top" char="." charoff="50">6 (20&#x00025;)</td><td align="char" valign="top" char="." charoff="50">16 (53&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Anaemia</td><td align="char" valign="top" char="." charoff="50">7 (23&#x00025;)</td><td align="char" valign="top" char="." charoff="50">18 (60&#x00025;)</td><td align="char" valign="top" char="." charoff="50">5 (17&#x00025;)</td><td align="char" valign="top" char="." charoff="50">&#x02014;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Thrombocytopaenia</td><td align="char" valign="top" char="." charoff="50">5 (17&#x00025;)</td><td align="char" valign="top" char="." charoff="50">3 (10&#x00025;)</td><td align="char" valign="top" char="." charoff="50">1 (3&#x00025;)</td><td align="char" valign="top" char="." charoff="50">&#x02014;</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Nonhaematological toxicity (30 patients)</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Fatigue</td><td align="char" valign="top" char="." charoff="50">8 (27&#x00025;)</td><td align="char" valign="top" char="." charoff="50">1 (3&#x00025;)</td><td align="char" valign="top" char="." charoff="50">&#x02014;</td><td align="char" valign="top" char="." charoff="50">&#x02014;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Anorexia</td><td align="char" valign="top" char="." charoff="50">9 (30&#x00025;)</td><td align="char" valign="top" char="." charoff="50">1 (3&#x00025;)</td><td align="char" valign="top" char="." charoff="50">1 (3&#x00025;)</td><td align="char" valign="top" char="." charoff="50">&#x02014;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Nausea</td><td align="char" valign="top" char="." charoff="50">6 (20&#x00025;)</td><td align="char" valign="top" char="." charoff="50">6 (20&#x00025;)</td><td align="char" valign="top" char="." charoff="50">4 (13&#x00025;)</td><td align="char" valign="top" char="." charoff="50">&#x02014;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Vomiting</td><td align="char" valign="top" char="." charoff="50">4 (13&#x00025;)</td><td align="char" valign="top" char="." charoff="50">3 (10&#x00025;)</td><td align="char" valign="top" char="." charoff="50">1 (3&#x00025;)</td><td align="char" valign="top" char="." charoff="50">&#x02014;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Constipation</td><td align="char" valign="top" char="." charoff="50">4 (13&#x00025;)</td><td align="char" valign="top" char="." charoff="50">&#x02014;</td><td align="char" valign="top" char="." charoff="50">&#x02014;</td><td align="char" valign="top" char="." charoff="50">&#x02014;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Diarrhoea</td><td align="char" valign="top" char="." charoff="50">3 (10&#x00025;)</td><td align="char" valign="top" char="." charoff="50">3 (10&#x00025;)</td><td align="char" valign="top" char="." charoff="50">&#x02014;</td><td align="char" valign="top" char="." charoff="50">&#x02014;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Stomatitis</td><td align="char" valign="top" char="." charoff="50">6 (20&#x00025;)</td><td align="char" valign="top" char="." charoff="50">1 (3&#x00025;)</td><td align="char" valign="top" char="." charoff="50">&#x02014;</td><td align="char" valign="top" char="." charoff="50">&#x02014;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Neuropathy</td><td align="char" valign="top" char="." charoff="50">8 (27&#x00025;)</td><td align="char" valign="top" char="." charoff="50">&#x02014;</td><td align="char" valign="top" char="." charoff="50">1 (3&#x00025;)</td><td align="char" valign="top" char="." charoff="50">&#x02014;</td></tr></tbody></table></table-wrap> summarises the toxicity observations. Grade 4 neutropaenia was observed in 16 patients (53&#x00025;). The patients who received 40&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> of epirubicin (EPI-40) experienced grade 4 neutropaenia more frequently than those receiving 30&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> of epirubicin (EPI-30) (88 <italic>vs</italic> 41&#x00025;, <italic>P</italic>&#x0003d;0.039). Febrile neutropaenia was observed more frequently in EPI-40 than EPI-30 (75 <italic>vs</italic> 32&#x00025;, <italic>P</italic>&#x0003d;0.034). Recurrent febrile neutropaenia was observed in four patients (one in EPI-30, three in EPI-40). No treatment-related mortality was observed.</p><p>Grade 3 nonhaematological toxicities were observed in some patients, including nausea, vomiting, anorexia and peripheral neuropathy. Grade 4 nonhaematological toxicity was not observed.</p></sec></sec><sec><title>DISCUSSION</title><p>We report the results of combination chemotherapy with EDP in metastatic gastric cancer patients. The response rate of 47&#x00025; and median survival of 11.0 months in this study indicate that this regimen is active against gastric cancer and worthy of further investigation.</p><p>The high prevalence in Korea of unresectable gastric cancer, the poor prognosis and slow improvement of treatment outcomes prompted us to develop a new regimen with high activity. The addition of taxane to active drug lists enabled us to broaden the selection of treatment options. Docetaxel in combination with cisplatin (<xref ref-type="other" rid="bib19">Roth <italic>et al</italic>, 2000</xref>; <xref ref-type="other" rid="bib17">Ridwelski <italic>et al</italic>, 2001</xref>) or epirubicin (<xref ref-type="other" rid="bib3">Andre <italic>et al</italic>, 1999</xref>) showed substantial response rates as first- and second-line chemotherapy in gastric cancer. An acceptable toxicity profile observed from experience in transitional cell carcinoma (<xref ref-type="other" rid="bib15">Pectasides <italic>et al</italic>, 2000</xref>) encouraged us to investigate this triple combination in gastric cancer.</p><p>We frequently encounter a response rate of 47&#x00025; in the setting of phase II studies in gastric cancer, but a median OS of 11.0 months is a favourable result. Although selection bias in phase II trials should be considered, median OS more than 10.0 months is not frequently reported. The well-proven regimen ECF reported high response rate of 71&#x00025;, but median OS was 8.2 months in a phase II trial (<xref ref-type="other" rid="bib8">Findlay <italic>et al</italic>, 1994</xref>), and 8.9 months and 9.4 months in phase III trials (<xref ref-type="other" rid="bib22">Webb <italic>et al</italic>, 1997</xref>; <xref ref-type="other" rid="bib18">Ross <italic>et al</italic>, 2002</xref>). An interim analysis of a large, randomised phase III trial comparing DCF and CF showed median OSs of 10.2 and 8.5 months, respectively (<xref ref-type="other" rid="bib2">Ajani <italic>et al</italic>, 2003</xref>).</p><p>The initial protocol with 40&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> epirubicin resulted in an unexpectedly high incidence of grade 4 neutropaenia (seven out of eight patients) and febrile neutropaenia (six out of eight patients). Therefore, we decided to reduce the epirubicin dose, and the subsequent 22 patients received 30&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> of epirubicin as a starting dose. More patients experienced febrile neutropaenia than those with transitional cell carcinoma who received the similar regimen (<xref ref-type="other" rid="bib15">Pectasides <italic>et al</italic>, 2000</xref>). The probable explanation is the less frequent use of haematopoietic growth factors in our study. In the previous study, the authors administered 75&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> docetaxel, 40&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> epirubicin and 75&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> cisplatin, and they used prophylactic haematopoietic growth factors with dose reduction in cases of grade 3&#x02013;4 neutropaenia and&#x0002f;or febrile neutropaenia (<xref ref-type="other" rid="bib15">Pectasides <italic>et al</italic>, 2000</xref>). However, we only reduced the dose in the subsequent cycles, without using prophylactic haematopoietic growth factor. We initially planned to include the patients with moderate liver function abnormality, that is, AST&#x0002f;ALT &#x0003c;5 times the UNL in case of liver metastasis. We speculated whether the generous inclusion criteria for liver function abnormality were responsible for the increased risk of neutropaenic fever. However, in this trial, no patients had AST&#x0002f;ALT &#x0003e;2.5 times the UNL irrespective of liver metastasis at the enrollment. Seven patients had pretreatment grade 1 liver function abnormality. Four (57&#x00025;) out of those seven patients experienced febrile neutropaenia and nine (39&#x00025;) out of 23 patients who had normal liver function test experienced that event (<italic>P</italic>&#x0003d;0.34).</p><p>During the follow-up period, 25 patients received second-line chemotherapy: 20 because of disease progression, and five because of SD status after EDP. We administered salvage treatment in five patients in the status of SD after EDP chemotherapy. We censored these patients at the time of initiating the salvage treatment for the calculation of TTP, and the median TTP was 4.1 months (95&#x00025; CI, 2.4&#x02013;5.9). We calculated again when we did not censor at that time and rather considered as an event at the time of progression after salvage treatment. The median TTP was 4.4 months (95&#x00025; CI, 2.6&#x02013;6.3) with this calculation method.</p><p>In conclusion, combination chemotherapy with EDP is active and relatively well tolerated in metastatic or recurrent, unresectable gastric cancer.</p></sec></body><back><ref-list><ref id="bib1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aabo</surname><given-names>K</given-names></name><name><surname>Pedersen</surname><given-names>H</given-names></name><name><surname>Rorth</surname><given-names>M</given-names></name></person-group><article-title>Cisplatin in the treatment of advanced gastric carcinoma: a phase II study</article-title><source>Cancer Treat Rep</source><year>1985</year><volume>69</volume><fpage>449</fpage><lpage>450</lpage><!--PubMed citation query: 'Cancer Treat Rep||69|449||bib1|'--><pub-id pub-id-type="pmid">4039628</pub-id></citation></ref><ref id="bib2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ajani</surname><given-names>JA</given-names></name><name><surname>Van Cutsem</surname><given-names>E</given-names></name><name><surname>Moiseyenko</surname><given-names>V</given-names></name><name><surname>Tjulandin</surname><given-names>S</given-names></name><name><surname>Fodor</surname><given-names>M</given-names></name><name><surname>Majlis</surname><given-names>A</given-names></name><name><surname>Boni</surname><given-names>C</given-names></name><name><surname>Zuber</surname><given-names>E</given-names></name><name><surname>Blattmannet</surname><given-names>A</given-names></name></person-group><article-title>Docetaxel (D), cisplatin, 5-fluorouracil compare to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-na&#x000ef;ve patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): interim results of a randomized phase III trial (V325)</article-title><source>Proc Am Soc Clin Oncol</source><year>2003</year><volume>22</volume><fpage>249</fpage>abstract 999<!--PubMed citation query: 'Proc Am Soc Clin Oncol||22|249||bib2|'--></citation></ref><ref id="bib3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Andre</surname><given-names>T</given-names></name><name><surname>Louvet</surname><given-names>C</given-names></name><name><surname>Ychou</surname><given-names>M</given-names></name><name><surname>Gamelin</surname><given-names>E</given-names></name><name><surname>Mousseau</surname><given-names>M</given-names></name><name><surname>Carola</surname><given-names>E</given-names></name><name><surname>Assadourian</surname><given-names>S</given-names></name><name><surname>Gramont</surname><given-names>AD</given-names></name></person-group><article-title>Docetaxel&#x02013;epirubicin as second-line treatment for patients with advanced gastric cancer</article-title><source>Proc Am Soc Clin Oncol</source><year>1999</year><volume>18</volume><fpage>277a</fpage>abstract 1062<!--PubMed citation query: 'Proc Am Soc Clin Oncol||18|277a||bib3|'--></citation></ref><ref id="bib4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bae</surname><given-names>JM</given-names></name><name><surname>Won</surname><given-names>WJ</given-names></name><name><surname>Jung</surname><given-names>KW</given-names></name><name><surname>Park</surname><given-names>JG</given-names></name></person-group><article-title>Annual report of the Korea Central Cancer Registry Program 2000: based on registered data from 131 hospitals</article-title><source>Cancer Res Treat</source><year>2002</year><volume>34</volume><fpage>77</fpage><lpage>83</lpage><!--PubMed citation query: 'Cancer Res Treat||34|77||bib4|'--></citation></ref><ref id="bib5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cersosimo</surname><given-names>RJ</given-names></name><name><surname>Hong</surname><given-names>WK</given-names></name></person-group><article-title>Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue</article-title><source>J Clin Oncol</source><year>1986</year><volume>4</volume><fpage>425</fpage><lpage>439</lpage><!--PubMed citation query: 'J Clin Oncol||4|425||bib5|'--><pub-id pub-id-type="pmid">3005521</pub-id></citation></ref><ref id="bib6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cocconi</surname><given-names>G</given-names></name><name><surname>DeLisi</surname><given-names>V</given-names></name><name><surname>Di Blasio</surname><given-names>B</given-names></name></person-group><article-title>Randomized comparison of 5-FU alone or combined with mitomycin and cytarabine (MFC) in the treatment of advanced gastric cancer</article-title><source>Cancer Treat Rep</source><year>1982</year><volume>66</volume><fpage>1263</fpage><lpage>1266</lpage><!--PubMed citation query: 'Cancer Treat Rep||66|1263||bib6|'--><pub-id pub-id-type="pmid">7083233</pub-id></citation></ref><ref id="bib7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Einzig</surname><given-names>AI</given-names></name><name><surname>Neuberg</surname><given-names>D</given-names></name><name><surname>Remick</surname><given-names>SC</given-names></name><name><surname>Coatsworth</surname><given-names>S</given-names></name><name><surname>Rodriquez</surname><given-names>R</given-names></name><name><surname>Wiernik</surname><given-names>PH</given-names></name></person-group><article-title>Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293</article-title><source>Med Oncol</source><year>1996</year><volume>13</volume><fpage>87</fpage><lpage>93</lpage><!--PubMed citation query: 'Med Oncol||13|87||bib7|'--><pub-id pub-id-type="pmid">9013471</pub-id></citation></ref><ref id="bib8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Findlay</surname><given-names>M</given-names></name><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Norman</surname><given-names>A</given-names></name><name><surname>Mansi</surname><given-names>J</given-names></name><name><surname>Nicolson</surname><given-names>M</given-names></name><name><surname>Hickish</surname><given-names>T</given-names></name><name><surname>Nicolson</surname><given-names>V</given-names></name><name><surname>Nash</surname><given-names>A</given-names></name><name><surname>Sacks</surname><given-names>N</given-names></name><name><surname>Ford</surname><given-names>H</given-names></name><name><surname>Carter</surname><given-names>R</given-names></name><name><surname>Hill</surname><given-names>A</given-names></name></person-group><article-title>A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF)</article-title><source>Ann Oncol</source><year>1994</year><volume>5</volume><fpage>609</fpage><lpage>616</lpage><!--PubMed citation query: 'Ann Oncol||5|609||bib8|'--><pub-id pub-id-type="pmid">7993836</pub-id></citation></ref><ref id="bib9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Glimelius</surname><given-names>B</given-names></name><name><surname>Ekstrom</surname><given-names>K</given-names></name><name><surname>Hoffman</surname><given-names>K</given-names></name><name><surname>Graf</surname><given-names>W</given-names></name><name><surname>Sjoden</surname><given-names>PO</given-names></name><name><surname>Haglund</surname><given-names>U</given-names></name><name><surname>Svensson</surname><given-names>C</given-names></name><name><surname>Enander</surname><given-names>LK</given-names></name><name><surname>Linne</surname><given-names>T</given-names></name><name><surname>Sellstrom</surname><given-names>H</given-names></name><name><surname>Heuman</surname><given-names>R</given-names></name></person-group><article-title>Randomised comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer</article-title><source>Ann Oncol</source><year>1997</year><volume>8</volume><fpage>163</fpage><lpage>168</lpage><!--PubMed citation query: 'Ann Oncol||8|163||bib9|'--></citation></ref><ref id="bib10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kelsen</surname><given-names>D</given-names></name><name><surname>Atiq</surname><given-names>OT</given-names></name><name><surname>Saltz</surname><given-names>L</given-names></name><name><surname>Niedzwiecki</surname><given-names>D</given-names></name><name><surname>Ginn</surname><given-names>D</given-names></name><name><surname>Chapman</surname><given-names>D</given-names></name><name><surname>Heelan</surname><given-names>R</given-names></name><name><surname>Lightdale</surname><given-names>C</given-names></name><name><surname>Vinciguerra</surname><given-names>V</given-names></name><name><surname>Brennan</surname><given-names>M</given-names></name></person-group><article-title>FAMTX <italic>versus</italic> etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer</article-title><source>J Clin Oncol</source><year>1992</year><volume>10</volume><fpage>541</fpage><lpage>548</lpage><!--PubMed citation query: 'J Clin Oncol||10|541||bib10|'--><pub-id pub-id-type="pmid">1548519</pub-id></citation></ref><ref id="bib11"><citation citation-type="journal"><person-group person-group-type="author"><collab>Kyoto Research Group for Chemotherapy of Gastric Cancer</collab></person-group><article-title>A randomized, comparative study of combination chemotherapies in advanced gastric cancer: 5-fluorouracil and cisplatin (FP) <italic>versus</italic> 5-fluorouracil, cisplatin, and 4&#x02032;-epirubicin (FPEPIR)</article-title><source>Anticancer Res</source><year>1992</year><volume>12</volume><fpage>1983</fpage><lpage>1988</lpage><!--PubMed citation query: 'Anticancer Res||12|1983||bib11|'--><pub-id pub-id-type="pmid">1295444</pub-id></citation></ref><ref id="bib12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moertel</surname><given-names>CG</given-names></name><name><surname>Lavin</surname><given-names>PT</given-names></name></person-group><article-title>Phase II&#x02013;III chemotherapy studies in advanced gastric cancer. Eastern cooperative oncology group</article-title><source>Cancer Treat Rep</source><year>1979</year><volume>63</volume><fpage>1863</fpage><lpage>1869</lpage><!--PubMed citation query: 'Cancer Treat Rep||63|1863||bib12|'--><pub-id pub-id-type="pmid">393381</pub-id></citation></ref><ref id="bib13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ohtsu</surname><given-names>A</given-names></name><name><surname>Shimada</surname><given-names>Y</given-names></name><name><surname>Shirao</surname><given-names>K</given-names></name><name><surname>Ohtsu</surname><given-names>A</given-names></name><name><surname>Shimada</surname><given-names>Y</given-names></name><name><surname>Shirao</surname><given-names>K</given-names></name><name><surname>Boku</surname><given-names>N</given-names></name><name><surname>Hyodo</surname><given-names>I</given-names></name><name><surname>Saito</surname><given-names>H</given-names></name><name><surname>Yamamichi</surname><given-names>N</given-names></name><name><surname>Miyata</surname><given-names>Y</given-names></name><name><surname>Ikeda</surname><given-names>N</given-names></name><name><surname>Yamamoto</surname><given-names>S</given-names></name><name><surname>Fukuda</surname><given-names>H</given-names></name><name><surname>Yoshida</surname><given-names>S</given-names></name></person-group><article-title>Randomized phase III trial of fluorouracil alone <italic>versus</italic> fluorouracil plus cisplatin <italic>versus</italic> uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205)</article-title><source>J Clin Oncol</source><year>2003</year><volume>21</volume><fpage>54</fpage><lpage>59</lpage><!--PubMed citation query: 'J Clin Oncol||21|54||bib13|'--><pub-id pub-id-type="pmid">12506170</pub-id></citation></ref><ref id="bib14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pagani</surname><given-names>O</given-names></name><name><surname>Sessa</surname><given-names>C</given-names></name><name><surname>Nole</surname><given-names>F</given-names></name><name><surname>Crivellari</surname><given-names>D</given-names></name><name><surname>Lombardi</surname><given-names>D</given-names></name><name><surname>Thurlimann</surname><given-names>B</given-names></name><name><surname>Hess</surname><given-names>D</given-names></name><name><surname>Borner</surname><given-names>M</given-names></name><name><surname>Bauer</surname><given-names>J</given-names></name><name><surname>Martinelli</surname><given-names>G</given-names></name><name><surname>Graffeo</surname><given-names>R</given-names></name><name><surname>Zucchetti</surname><given-names>M</given-names></name><name><surname>D'Incalci</surname><given-names>M</given-names></name><name><surname>Goldhirsch</surname><given-names>A</given-names></name></person-group><article-title>Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I&#x02013;II study</article-title><source>Ann Oncol</source><year>2000</year><volume>11</volume><fpage>985</fpage><lpage>991</lpage><!--PubMed citation query: 'Ann Oncol||11|985||bib14|'--><pub-id pub-id-type="pmid">11038035</pub-id></citation></ref><ref id="bib15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pectasides</surname><given-names>D</given-names></name><name><surname>Visvikis</surname><given-names>A</given-names></name><name><surname>Aspropotamitis</surname><given-names>A</given-names></name><name><surname>Halikia</surname><given-names>A</given-names></name><name><surname>Karvounis</surname><given-names>N</given-names></name><name><surname>Dimitriadis</surname><given-names>M</given-names></name><name><surname>Athanassiou</surname><given-names>A</given-names></name></person-group><article-title>Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial</article-title><source>Eur J Cancer</source><year>2000</year><volume>36</volume><fpage>74</fpage><lpage>79</lpage><!--PubMed citation query: 'Eur J Cancer||36|74||bib15|'--><pub-id pub-id-type="pmid">10741298</pub-id></citation></ref><ref id="bib16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pyrhonen</surname><given-names>S</given-names></name><name><surname>Kuitunen</surname><given-names>T</given-names></name><name><surname>Nyandoto</surname><given-names>P</given-names></name><name><surname>Kouri</surname><given-names>M</given-names></name></person-group><article-title>Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer</article-title><source>Br J Cancer</source><year>1995</year><volume>71</volume><fpage>587</fpage><lpage>591</lpage><!--PubMed citation query: 'Br J Cancer||71|587||bib16|'--><pub-id pub-id-type="pmid">7533517</pub-id></citation></ref><ref id="bib17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ridwelski</surname><given-names>K</given-names></name><name><surname>Gebauer</surname><given-names>T</given-names></name><name><surname>Fahlke</surname><given-names>J</given-names></name><name><surname>Kroning</surname><given-names>H</given-names></name><name><surname>Kettner</surname><given-names>E</given-names></name><name><surname>Meyer</surname><given-names>F</given-names></name><name><surname>Eichelmann</surname><given-names>K</given-names></name><name><surname>Lippert</surname><given-names>H</given-names></name></person-group><article-title>Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer</article-title><source>Ann Oncol</source><year>2001</year><volume>12</volume><fpage>47</fpage><lpage>51</lpage><!--PubMed citation query: 'Ann Oncol||12|47||bib17|'--><pub-id pub-id-type="pmid">11249048</pub-id></citation></ref><ref id="bib18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>P</given-names></name><name><surname>Nicolson</surname><given-names>M</given-names></name><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Valle</surname><given-names>J</given-names></name><name><surname>Seymour</surname><given-names>M</given-names></name><name><surname>Harper</surname><given-names>P</given-names></name><name><surname>Price</surname><given-names>T</given-names></name><name><surname>Anderson</surname><given-names>H</given-names></name><name><surname>Iveson</surname><given-names>T</given-names></name><name><surname>Hickish</surname><given-names>T</given-names></name><name><surname>Lofts</surname><given-names>F</given-names></name><name><surname>Norman</surname><given-names>A</given-names></name></person-group><article-title>Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer</article-title><source>J Clin Oncol</source><year>2002</year><volume>20</volume><fpage>1996</fpage><lpage>2004</lpage><!--PubMed citation query: 'J Clin Oncol||20|1996||bib18|'--><pub-id pub-id-type="pmid">11956258</pub-id></citation></ref><ref id="bib19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname><given-names>AD</given-names></name><name><surname>Maibach</surname><given-names>R</given-names></name><name><surname>Martinelli</surname><given-names>G</given-names></name><name><surname>Fazio</surname><given-names>N</given-names></name><name><surname>Aapro</surname><given-names>MS</given-names></name><name><surname>Pagani</surname><given-names>O</given-names></name><name><surname>Morant</surname><given-names>R</given-names></name><name><surname>Borner</surname><given-names>MM</given-names></name><name><surname>Herrmann</surname><given-names>R</given-names></name><name><surname>Honegger</surname><given-names>H</given-names></name><name><surname>Cavalli</surname><given-names>F</given-names></name><name><surname>Alberto</surname><given-names>P</given-names></name><name><surname>Castiglione</surname><given-names>M</given-names></name><name><surname>Goldhirsch</surname><given-names>A</given-names></name></person-group><article-title>Docetaxel (Taxotere)&#x02013;cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO)</article-title><source>Ann Oncol</source><year>2000</year><volume>11</volume><fpage>301</fpage><lpage>306</lpage><!--PubMed citation query: 'Ann Oncol||11|301||bib19|'--><pub-id pub-id-type="pmid">10811496</pub-id></citation></ref><ref id="bib20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sulkes</surname><given-names>A</given-names></name><name><surname>Smyth</surname><given-names>J</given-names></name><name><surname>Sessa</surname><given-names>C</given-names></name><name><surname>Dirix</surname><given-names>LY</given-names></name><name><surname>Vermorken</surname><given-names>JB</given-names></name><name><surname>Kaye</surname><given-names>S</given-names></name><name><surname>Wanders</surname><given-names>J</given-names></name><name><surname>Franklin</surname><given-names>H</given-names></name><name><surname>LeBail</surname><given-names>N</given-names></name><name><surname>Verweij</surname><given-names>J</given-names></name></person-group><article-title>Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group</article-title><source>Br J Cancer</source><year>1994</year><volume>70</volume><fpage>380</fpage><lpage>383</lpage><!--PubMed citation query: 'Br J Cancer||70|380||bib20|'--><pub-id pub-id-type="pmid">7914428</pub-id></citation></ref><ref id="bib21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vorobiof</surname><given-names>DA</given-names></name><name><surname>Falkson</surname><given-names>G</given-names></name></person-group><article-title>Phase II study of high-dose 4&#x02032;-epidoxorubicin in the treatment of advanced gastrointestinal cancer</article-title><source>Eur J Cancer Clin Oncol</source><year>1989</year><volume>25</volume><fpage>563</fpage><lpage>564</lpage><!--PubMed citation query: 'Eur J Cancer Clin Oncol||25|563||bib21|'--><pub-id pub-id-type="pmid">2703009</pub-id></citation></ref><ref id="bib22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Webb</surname><given-names>A</given-names></name><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Scarffe</surname><given-names>JH</given-names></name><name><surname>Harper</surname><given-names>P</given-names></name><name><surname>Norman</surname><given-names>A</given-names></name><name><surname>Joffe</surname><given-names>JK</given-names></name><name><surname>Hughes</surname><given-names>M</given-names></name><name><surname>Mansi</surname><given-names>J</given-names></name><name><surname>Findlay</surname><given-names>M</given-names></name><name><surname>Hill</surname><given-names>A</given-names></name><name><surname>Oates</surname><given-names>J</given-names></name><name><surname>Nicolson</surname><given-names>M</given-names></name><name><surname>Hickish</surname><given-names>T</given-names></name><name><surname>O'Brien</surname><given-names>M</given-names></name><name><surname>Iveson</surname><given-names>T</given-names></name><name><surname>Watson</surname><given-names>M</given-names></name><name><surname>Underhill</surname><given-names>C</given-names></name><name><surname>Wardley</surname><given-names>A</given-names></name><name><surname>Meehan</surname><given-names>M</given-names></name></person-group><article-title>Randomized trial comparing epirubicin, cisplatin, and fluorouracil <italic>versus</italic> fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer</article-title><source>J Clin Oncol</source><year>1997</year><volume>15</volume><fpage>261</fpage><lpage>267</lpage><!--PubMed citation query: 'J Clin Oncol||15|261||bib22|'--><pub-id pub-id-type="pmid">8996151</pub-id></citation></ref><ref id="bib23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilke</surname><given-names>H-J</given-names></name><name><surname>Cutsem</surname><given-names>EV</given-names></name></person-group><article-title>Current treatment and future perspectives in colorectal and gastric cancer</article-title><source>Ann Oncol</source><year>2003</year><volume>14</volume><supplement>(Suppl 2)</supplement><fpage>ii49</fpage><lpage>ii55</lpage><!--PubMed citation query: 'Ann Oncol||14|ii49||bib23|'--><pub-id pub-id-type="pmid">12810459</pub-id></citation></ref><ref id="bib24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wils</surname><given-names>JA</given-names></name><name><surname>Klein</surname><given-names>HO</given-names></name><name><surname>Wagener</surname><given-names>DJ</given-names></name><name><surname>Bleiberg</surname><given-names>H</given-names></name><name><surname>Reis</surname><given-names>H</given-names></name><name><surname>Korsten</surname><given-names>F</given-names></name><name><surname>Conroy</surname><given-names>T</given-names></name><name><surname>Fickers</surname><given-names>M</given-names></name><name><surname>Leyvraz</surname><given-names>S</given-names></name><name><surname>Buyse</surname><given-names>M</given-names></name></person-group><article-title>Sequential high-dose methotrexate and fluorouracil combined with doxorubicin: a step ahead in the treatment of advanced gastric cancer: a trial of the EORTC Gastrointestinal Tract Cooperative Group</article-title><source>J Clin Oncol</source><year>1991</year><volume>9</volume><fpage>827</fpage><lpage>831</lpage><!--PubMed citation query: 'J Clin Oncol||9|827||bib24|'--><pub-id pub-id-type="pmid">2016625</pub-id></citation></ref></ref-list></back></article>


